Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.33 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 5/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28665586 | 1.00 | PPARA (0.35) | PPARACREBBPPPARGCTSSGSTP1 | |
| SCHEMBL22411874 | 0.88 | CREBBP (0.37) | CREBBPGAAMEN1KMT2A | |
| SCHEMBL28687446 | 0.83 | ALDH1A1 (0.42) | PPARAPPARGCTSSGSTP1GSTM2 | |
| SCHEMBL31172085 | 0.83 | ALDH1A1 (0.42) | PPARAPPARGCTSSGSTP1GSTM2 | |
| SCHEMBL28665584 | 0.83 | CREBBP (0.35) | CREBBPGAAMEN1KMT2A | |
| SCHEMBL31681403 | 0.79 | — | — | |
| SCHEMBL22411929 | 0.79 | — | — | |
| SCHEMBL22412042 | 0.79 | CREBBP (0.36) | CREBBPGAAMEN1KMT2A | |
| SCHEMBL22412040 | 0.79 | CREBBP (0.36) | CREBBPGAAMEN1KMT2A | |
| SCHEMBL31172072 | 0.79 | CREBBP (0.36) | CREBBPGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2025-09-04 | — | — | US | disclosed |
| CN-113811534-B | TYK2 inhibitors and uses thereof | 阿鲁米斯公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | PPARA 2062/4885CREBBP 761/4885PPARG 2574/4885 |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | PPARA 2062/4885CREBBP 761/4885PPARG 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.